Complementary meds used by 17 percent of elderly with cancer

March 2, 2012
Complementary meds used by 17 percent of elderly with cancer

(HealthDay) -- The prevalence of older people with cancer using complementary medications as they start a chemotherapy regimen is 17 percent, and is associated with less advanced disease and higher functional status, according to a study published online Feb. 22 in Cancer.

Ronald J. Maggiore, M.D., of the University of Chicago Medical Center, and colleagues evaluated the prevalence of complementary medicine use as well as factors associated with its use among 545 patients (mean age, 73 years) about to start chemotherapy for cancer (61 percent stage IV).

The researchers found that 17 percent of patients reported using at least one complementary medication, with a mean of two medications used per patient. There was an association between complementary medication use and earlier (stage I to II, 29 percent; stage III to IV, 17 percent; odds ratio [OR], 2.05) as well as less impairment in instrumental activities of daily living (OR, 1.39).

"Complementary medication use was reported by 17 percent of older adults with cancer and was more common among those who had less advanced disease (i.e., those receiving adjuvant, potentially curative treatment) and higher functional status," the authors write. "Further studies are needed to determine the association between complementary medication use and cancer outcomes among ."

One of the authors disclosed to the pharmaceutical industry.

Explore further: Study showed oxaliplatin improved colon cancer patient survival

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Study showed oxaliplatin improved colon cancer patient survival

January 20, 2012
Stage III colon cancer patients in the general population who receive adjuvant treatment for the disease have an improved rate of survival when oxaliplatin is added to 5-fluorouracil (5FU), according to a study published ...

Recommended for you

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

Newest data links inflammation to chemo-brain

December 14, 2017
Inflammation in the blood plays a key role in "chemo-brain," according to a published pilot study that provides evidence for what scientists have long believed.

One in five young colon cancer patients have genetic link

December 13, 2017
As doctors grapple with increasing rates of colorectal cancers in young people, new research from the University of Michigan may offer some insight into how the disease developed and how to prevent further cancers. Researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.